Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

3′-18F-Fluoro-3′-Deoxy-l-Thymidine: A New Tracer for Staging Metastatic Melanoma?

David C.P. Cobben, Piet L. Jager, Philip H. Elsinga, Bram Maas, Albert J.H. Suurmeijer and Harald J. Hoekstra
Journal of Nuclear Medicine December 2003, 44 (12) 1927-1932;
David C.P. Cobben
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piet L. Jager
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip H. Elsinga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bram Maas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert J.H. Suurmeijer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harald J. Hoekstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    18F-FLT PET of 34-y-old man (patient 6) 2 mo after resection of primary melanoma on back. Metastases (large arrows) are observed in left and right axillae and left supraclavicular area. Physiologic uptake (small arrows) is observed in liver and 1 marrow—for example, in pelvis, vertebrae, ribs, and bony structures of shoulder; less intense, uniform tracer uptake is present in lungs. Uptake of tracer in brain is negligible, and no uptake is observed in mediastinum and myocardium.

Tables

  • Figures
    • View popup
    TABLE 1

    Patient Characteristics

    Patient no.Age (y)SexClark levelBreslow thickness (mm)Locoregional disease
    148F**Groin
    239FIV1.8Groin
    342MIV4.1Axilla
    473MIV4.4Groin
    578MIV1Groin
    634M†6Axillae
    740MIV1.35Axilla
    829M**Groin
    940FIII0.7Axilla
    1054M†>4Groin
    • ↵* Unknown primary.

    • ↵† Primary melanoma too small to assess Clark level.

    • View popup
    Table 2

    Cross of FLT PET Regions Compared with Histopathologic Regions

    ComparisonFLT +FLT −
    Histopathology +223
    Histopathology −23
    • Sensitivity = 88%; specificity = 60%.

    • View popup
    TABLE 3

    False-Negative, False-Positive, and Additional FLT PET Findings

    LocationNo. of lesionsPAResultDiagnostics
    Deep groin1PosFNAspiration cytology
    Dermal or subcutaneous metastases on back9PosFNHistopathology
    Back (primary tumor)1PosFNHistopathology
    Deep groin1NegFPHistopathology
    Leg (heel)1NegFPReresection in 1998 negative and clinically negative, follow-up of 5 y
    Mediastinal3NPFNCT
    Thoracic vertebra1NPFNCT
    Lumbar vertebra1NPNABone scan with multiple bone metastases (also spinal) 2.5 mo after PET
    Fossa poplitea1NPNAClinically negative, follow-up of 4 mo
    Mediastinal1NPTNCT
    Paraaortal1NPTNCT
    Head and neck2NPTNClinically negative, follow-up of 3 mo
    Mediastinal2NPTPCT
    Paraaortal2NPTPCT
    Supraclavicular1NPTPPhysical examination
    • PA = pathologic examination.

    • Pos = positive; FN = false-negative; Neg = negative; FP = false-positive; NP = not performed; NA = not assessable; TN = true-negative; TP = true-positive.

    • View popup
    TABLE 4

    Staging

    Patient no.Clinical stagingPET stagingPathologic staging
    TNStageNMStageTN*MStage
    1†+III+0III†p2b0IIIB
    22a+III+1IV2ap31cIV
    34b+III+0III4bp30IIIC
    44b+III+1IV4bp31cIV
    51a+III+0III1ap30IIIC
    64b+III+0III4bp30IIIC
    72a+III+0III2ap1b0IIIB
    8†+III+0III†p30IIIC
    91a+III+0III1ap1b0IIIB
    104b+III+0III4bp30IIIC
    • ↵* All patients had locoregional lesions visualized by FLT PET.

    • ↵† Unknown primary.

    • + = positive lymph nodes on physical or cytologic examination.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 44, Issue 12
December 1, 2003
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
3′-18F-Fluoro-3′-Deoxy-l-Thymidine: A New Tracer for Staging Metastatic Melanoma?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
3′-18F-Fluoro-3′-Deoxy-l-Thymidine: A New Tracer for Staging Metastatic Melanoma?
David C.P. Cobben, Piet L. Jager, Philip H. Elsinga, Bram Maas, Albert J.H. Suurmeijer, Harald J. Hoekstra
Journal of Nuclear Medicine Dec 2003, 44 (12) 1927-1932;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
3′-18F-Fluoro-3′-Deoxy-l-Thymidine: A New Tracer for Staging Metastatic Melanoma?
David C.P. Cobben, Piet L. Jager, Philip H. Elsinga, Bram Maas, Albert J.H. Suurmeijer, Harald J. Hoekstra
Journal of Nuclear Medicine Dec 2003, 44 (12) 1927-1932;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Ultrasensitive detection of malignant melanoma using PET molecular imaging probes
  • PET Imaging of Proliferation with Pyrimidines
  • Noninvasive Imaging of Endogenous Neural Stem Cell Mobilization In Vivo Using Positron Emission Tomography
  • PET of Malignant Melanoma Using 18F-Labeled Metallopeptides
  • Melanin-Targeted Preclinical PET Imaging of Melanoma Metastasis
  • 18F-FLT PET in Hematologic Disorders: A Novel Technique to Analyze the Bone Marrow Compartment
  • Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
  • 18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors
  • Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice
  • Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
  • Comparison of 18F-FLT PET and 18F-FDG PET in Esophageal Cancer
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire